MedChemExpress

## Product Data Sheet

MD6a

| Cat. No.: | $\mathrm{HY}-162363$ |
| :--- | :--- |
| Molecular Formula: | $\mathrm{C}_{21} \mathrm{H}_{22} \mathrm{~N}_{2} \mathrm{O}_{2}$ |
| Molecular Weight: | 334.41 |
| Target: | PARP |
| Pathway: | Cell Cycle/DNA Damage; Epigenetics |
| Storage: | Please store the product under the recommended conditions in the Certificate of |
| Analysis. |  |

## BIOLOGICAL ACTIVITY

Description

In Vitro

MD6a is a melatonin derivative with inhibitroy activity towards PARP-1, which maintains proteins hemostasis and improves mitochondrial function through TOR/HSF-1 signaling. MD6a a neuroprotective effect ${ }^{[1]}$.

MD6a ( $10 \mu \mathrm{M}$ ) inhibits PARP-1 to downregulate let-363/hsf-1 signaling by targeting hsp-4 and hsp-6, thus reducing $\alpha$-syn aggregation and enhances mitochondrial function in C. elegans ${ }^{[1]}$.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Real Time qPCR ${ }^{[1]}$

Cell Line: $\quad$ wildtype N2, NL5901, parp-1 RNAi

Concentration: $10 \mu \mathrm{M}$

| Incubation Time: | 48 h |
| :--- | :--- |

Result
Reduced levels of parp-1 mRNA, parp-1 dependent $\alpha$-syn aggregation and mitochondrial ROS levels

## REFERENCES

[1]. Ma QW, et al., Melatonin derivative 6a as a PARP-1 inhibitor for the treatment of Parkinson's disease. Front Pharmacol. 2024 Feb 27;15:1363212.

Caution: Product has not been fully validated for medical applications. For research use only.
Tel: 609-228-6898 Fax: 609-228-5909 E-mail:tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

